Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siplizumab in Type 1 Diabetes Mellitus
NCT05574335Phase 2Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- May 2023
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of siplizumab in type 1 diabetes mellitus (T1D) (8 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Number of Participants With a T Cell Phenotype Signature Response at 12 weeks. Started May 2023; status: terminated.
02
Drugs
siplizumab
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT05574335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05574335.